REGENEREX, LLC

Basic Information

201 E JEFFERSON ST
LOUISVILLE, KY, 40202-

Company Profile

n/a

Additional Details

Field Value
DUNS: 140644969
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Delayed Tolerance Induction in Living Related Donor Renal Transplant Recipients

    Amount: $299,662.00

    DESCRIPTION (provided by applicant): We have developed a protocol that reproducibly induces transplantation tolerance in individuals undergoing a living related donor kidney transplant. Three subjects ...

    STTR Phase I 2012 Department of Health and Human Services
  2. Induction of Donor Tolerance in Renal Transplants

    Amount: $3,600,135.00

    DESCRIPTION: Renal transplantation is the preferred therapeutic approach for end organ failure. However, the chronic use of immunosuppressive agents is critical to prevent rejection. The drugs are cos ...

    STTR Phase II 2011 Department of Health and Human Services
  3. Stem Cell Graft Engineering to Treat Sickle Cell Disease

    Amount: $1,414,979.00

    DESCRIPTION (provided by applicant): Sickle Cell Disease (SCD) is a genetic abnormality of red blood cells (RBC) that affects over 70,000 people in the United States, or approximately 1 in every 500 A ...

    STTR Phase II 2008 Department of Health and Human Services
  4. Induction of Donor Tolerance in Renal Transplants

    Amount: $447,862.00

    DESCRIPTION (provided by applicant): Bone marrow transplantation (BMT) can treat sickle cell anemia, type 1 diabetes, multiple sclerosis and other autoimmune disorders, and induces immune tolerance in ...

    STTR Phase I 2005 Department of Health and Human Services
  5. AMD-FCRx to Restore Damaged Pigment Epithelium

    Amount: $355,139.00

    DESCRIPTION (provided by applicant): Age-related macular degeneration (AMD) is the leading cause of blindness in the Western world. The hallmark of the disease is retinal pigment epithelial (RPE) dysf ...

    STTR Phase I 2005 Department of Health and Human Services
  6. Stem Cell Graft Engineering to Treat Sickle Cell Disease

    Amount: $220,500.00

    DESCRIPTION (provided by applicant): Sickle Cell Disease (SCD) is an abnormality of red blood cells (RBC) that affects approximately 72,000 people in the United States, or approximately 1 in every 500 ...

    STTR Phase I 2004 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government